Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, submitted in August 2025, met the relevant requirements for drug registration, and approval was granted to proceed with clinical trials.

HSK39297 tablets are a novel, independently developed drug with proprietary intellectual property rights for treating age-related macular degeneration (AMD). Preclinical research results indicate that the drug has a clear target, proven efficacy, and favorable safety, making it a highly promising small-molecule drug. With a high benefit/risk ratio and broad clinical application prospects, HSK39297 tablets are expected to become an effective treatment for AMD, addressing the current shortage of clinical therapies for this condition.